Cyclophosphamide-based stem cell mobilization in relapsed multiple myeloma patients: A subgroup analysis from the phase III trial ReLApsE

Baertsch Marc-Andrea; Schlenzka Jana; Lisenko Katharina; Krzykalla Julia; Becker Natalia; Weisel Katja; Noppeney Richard; Martin Hans; Lindemann Hans W.; Haenel Mathias; Nogai Axel; Scheid Christof; Salwender Hans; Fenk Roland; Graeven Ullrich; Reimer Peter; Schmidt-Hieber Martin; Goerner Martin; Schmidt-Wolf Ingo G. H.; Klein Stefan; Ho Anthony D.; Goldschmidt Hartmut; Wuchter Patrick

首页> 外文期刊>European Journal of Haematology >Cyclophosphamide-based stem cell mobilization in relapsed multiple myeloma patients: A subgroup analysis from the phase III trial ReLApsE

【24h】

Cyclophosphamide-based stem cell mobilization in relapsed multiple myeloma patients: A subgroup analysis from the phase III trial ReLApsE

机译：基于环磷酰胺的干细胞动员在复发多发性骨髓瘤患者中：III期试次复发的亚组分析

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

ObjectiveAnalysis of the efficiency and toxicity of cyclophosphamide-based stem cell mobilization in patients with relapsed multiple myeloma (RMM).

机译：复发多重骨髓瘤（RMM）患者环磷酰胺基干细胞动员效率和毒性的对象分析。

著录项

来源
《European Journal of Haematology》 |2017年第1期|共9页
作者
Baertsch Marc-Andrea; Schlenzka Jana; Lisenko Katharina; Krzykalla Julia; Becker Natalia; Weisel Katja; Noppeney Richard; Martin Hans; Lindemann Hans W.; Haenel Mathias; Nogai Axel; Scheid Christof; Salwender Hans; Fenk Roland; Graeven Ullrich; Reimer Peter; Schmidt-Hieber Martin; Goerner Martin; Schmidt-Wolf Ingo G. H.; Klein Stefan; Ho Anthony D.; Goldschmidt Hartmut; Wuchter Patrick;
展开▼
作者单位

Univ Hosp Heidelberg Dept Med 5 Heidelberg Germany;

Univ Hosp Heidelberg Dept Med 5 Heidelberg Germany;

Univ Hosp Heidelberg Dept Med 5 Heidelberg Germany;

German Canc Res Ctr Biostat Heidelberg Germany;

German Canc Res Ctr Biostat Heidelberg Germany;

Univ Tubingen Hematol Oncol &

Immunol Tubingen Germany;

Univ Hosp Essen Hematol Essen Germany;

Goethe Univ Hematol &

Oncol Frankfurt Germany;

St Marien Hosp Hematol &

Oncol Kath Krankenhaus Hagen Gem GmbH Hagen Germany;

Klinikum Chemnitz GmbH Hematol Oncol &

Stem Cell Transplantat Chemnitz Germany;

Charite Campus Benjamin Franklin Internal Med 3 Berlin Germany;

Univ Cologne Internal Med Cologne Germany;

Asklepios Klin Altona Hematol Oncol &

Palliat Care Hamburg Germany;

Univ Duesseldorf Hematol Oncol &

Clin Immunol Dusseldorf Germany;

Maria Hilf Krankenhaus Hematol Oncol &

Gastroenterol Monchengladbach Germany;

Evangel Krankenhaus Essen Werden gGmbH Hematol Oncol &

Stem Cell Transplantat Essen Germany;

Helios Hosp Berlin Buch Hematol &

Oncol Berlin Germany;

Community Hosp Bielefeld Hematol Oncol &

Palliat Care Bielefeld Germany;

Univ Hosp Bonn Med Klin 3 Ctr Integrated Oncol Bonn Germany;

Univ Hosp Mannheim Hematol &

Oncol Mannheim Germany;

Univ Hosp Heidelberg Dept Med 5 Heidelberg Germany;

Univ Hosp Heidelberg Dept Med 5 Heidelberg Germany;

Univ Hosp Heidelberg Dept Med 5 Heidelberg Germany;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类血液及淋巴系疾病;
关键词
bone marrow transplantation; clinical trials; multiple myeloma;

机译：骨髓移植;临床试验;多发性骨髓瘤;

相似文献

外文文献
中文文献
专利

1. Cyclophosphamide-based stem cell mobilization in relapsed multiple myeloma patients: A subgroup analysis from the phase III trial ReLApsE [J] . Baertsch Marc-Andrea, Schlenzka Jana, Lisenko Katharina, European Journal of Haematology . 2017,第1期

机译：基于环磷酰胺的干细胞动员在复发多发性骨髓瘤患者中：III期试次复发的亚组分析
2. High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): A randomised, open-label, phase 3 trial [J] . CookG., WilliamsC., BrownJ.M., The lancet oncology . 2014,第8期

机译：大剂量化疗加自体干细胞移植作为巩固疗法治疗先前自体干细胞移植后复发的多发性骨髓瘤患者（NCRI骨髓瘤X复发[强化试验]）：一项随机，开放标签的3期试验
3. Carfilzomib in relapsed or refractory multiple myeloma patients with early or late relapse following prior therapy: A subgroup analysis of the randomized phase 3 ASPIRE and ENDEAVOR trials [J] . Mateos Maria‐Victoria, Goldschmidt Hartmut, San‐Miguel Jesus, Hematological oncology . 2018,第2期

机译：在先前治疗之后，Carfilzomib在复发或难倒的多发性骨髓瘤患者的早期或晚期复发：随机阶段3的亚组分析，渴望和努力试验
4. Durability of Response with Thalidomide Therapy for Relapsed Multiple Myeloma [C] . B. Myers, S.G. Jones, G. Do I an European Haematology Association . 2002

机译：耐久性耐久性与多发性骨髓瘤复发疗法
5. A Phase 1/2 Study of Ixazomib as a Replacement for Bortezomib or Carfilzomib for Multiple Myeloma Patients Recently Relapsed or Refractory to Their Last Combination Regimen Containing Either Bortezomib or Carfilzomib [D] . Forouzan, Eli. 2020

机译：Ixazomib的第1/2期作为替代品髓鞘或胭脂瘤患者的替代品的替代物，最近对含有Bortezomib或Carfilzomib的最后组合方案复发或难治
6. Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized open multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma [O] . Marc-Andrea Baertsch, Jana Schlenzka, Elias K. Mai, 2016

机译：德语德语骨髓瘤多中心小组（GMMG）试验ReLApsE的原理和设计：来那度胺/地塞米松与来那度胺/地塞米松联合随后自体干细胞移植和来那度胺维持治疗多发性骨髓瘤的患者的随机开放多中心III期试验
7. Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE : a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma [O] . Bärtsch, Marc-Andrea, Schlenzka, Jana, Mai, Elias K., 2017

机译：德语系骨髓瘤多中心小组（RelepsE）试验的原理和设计：来那度胺/地塞米松与来那度胺/地塞米松联合随后的自体干细胞移植和来那度胺维持治疗多发性骨髓瘤的患者的随机，开放，多中心III期试验

Cyclophosphamide-based stem cell mobilization in relapsed multiple myeloma patients: A subgroup analysis from the phase III trial ReLApsE

摘要

著录项

相似文献

相关主题

期刊订阅